ANI Pharmaceuticals | ANIP - Sales Revenues


ANI Pharmaceuticals reported $266M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Perrigo USD 1.02B 51M Jun/2026
Sun Pharmaceuticals INR 153B 7.14B Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026